Go Deep
Carna Biosciences, Inc.
Carna Biosciences, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -30,463 | -3.1 | -18.10 | 2.31 | 211.27 |
Carna Biosciences, Inc. Quarterly Results
| Line Item | Mar 2026 | Mar 2025 |
|---|---|---|
| EPS | -26.8 | -26.1 |
Carna Biosciences, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 579,057,000.0 | 636,235,000.0 | 1,625,889,000.0 | 1,386,748,000.0 |
| Net Profit | -2,171,470,000.0 | -2,178,576,000.0 | -1,152,895,000.0 | -1,349,539,000.0 |
| EPS | -113.6 | -121.6 | -68.6 | -99.1 |
Carna Biosciences, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 1,229,648,000.0 | 2,772,115,000.0 | 4,349,891,000.0 | 4,266,453,000.0 | — |
| Total Liabilities | 920,430,000.0 | 296,761,000.0 | 472,356,000.0 | 624,608,000.0 | — |
| Total Equity | 309,218,000.0 | 2,475,354,000.0 | 3,877,535,000.0 | 3,641,845,000.0 | — |
Owes vs Owns
Carna Biosciences, Inc. owed ¥1.23 for every ¥1 it owned in Jun 2026, up from ¥0.15 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 1.23× | 0.75× | 0.11× | 0.11× | 0.15× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Carna Biosciences, Inc. Assets & Liabilities Breakdown (JPY millions)
What it owns — Dec 2025
Cash & short-term investments 42.0%Receivables 8.2%Inventory 12.5%Other assets 37.3%
How it's funded — Dec 2025
Short-term debt 0.7%Long-term debt 55.4%Other liabilities 18.7%Shareholders' equity 25.1%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 516.8 | 2,108.5 | 2,889.1 | 3,379.0 |
| Receivables | 100.5 | 87.1 | 788.2 | 182.4 |
| Inventory | 154.1 | 154.1 | 140.1 | 118.5 |
| Fixed assets (tangible) | 0.0 | 0.0 | 105.5 | 100.2 |
| Intangible assets | 0.0 | 0.0 | 1.1 | 1.9 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 458.2 | 422.4 | 425.9 | 484.3 |
| Liabilities & equity | ||||
| Short-term debt | 8.4 | 20.0 | 120.0 | 152.0 |
| Long-term debt | 681.2 | 8.4 | 28.4 | 148.4 |
| Payables | 0.5 | 2.0 | 1.2 | 2.0 |
| Other liabilities | 230.3 | 266.4 | 322.8 | 322.3 |
| Shareholders' equity | 309.2 | 2,475.4 | 3,877.5 | 3,641.8 |
| Net tangible assets | 309.2 | 2,475.4 | 3,876.4 | 3,639.9 |
Carna Biosciences, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -2,159,363,000.0 | -1,374,806,000.0 | -1,677,464,000.0 | -708,390,000.0 | — |
| Investing Activities | -25,009,000.0 | -13,060,000.0 | -11,376,000.0 | -125,696,000.0 | — |
| Financing Activities | 604,711,000.0 | 567,441,000.0 | 1,182,027,000.0 | 367,006,000.0 | — |